Bispecifics in Oncology and IO: Anything One Can Do, Can Two Do Better?
In this web panel discussion, biotech licensing and pharmaceutical business development consultant Linda Pullan is joined by six panelists – scientific and business development experts representing leading biotech, pharmaceutical and consulting organizations to discuss the science and business of bispecifics and related multivalent cancer therapeutics. Request a copy today!
Synopsis of the discussion:
As Immuno-Oncology continues to be at the forefront of oncology, the platforms continue to expand and evolve: from antibodies against checkpoint inhibitors to heavily engineered adoptive cell therapies (ACT) like CAR-T and RNA-based Neoantigen vaccines. Perhaps the next wave is around bispecific antibodies and related multivalent biologics.
These "bispecific" technologies essentially come in two flavors of two-for-one activities: (1) they can be combinations of antagonists with two checkpoint inhibitors (CPI) in a single molecule (or a combination of a CPI and a costimulatory agonist), or (2) they can redirect immune cells by dual targeting of a cell surface receptor/antigen and an immune cell target such as CD3 on T-cells, obviating the need for ex vivo cell manipulation as with CAR-Ts. These bispecifics thus may offer several value propositions including improved therapeutic index (especially for solid tumors), possibly improved convenience, and even better economics. However, challenges remain, both in achieving the dual targeting as well as in on-target off-tissue AEs and cytokine release syndrome.
Leading players such as Micromet/Amgen, Xencor, MacroGenics and others, plus newer entrants such as f-star, Pieris, immatics, Crescendo and Shattuck Labs, have been pushing bispecific platforms, and numerous high profile partnerships have been enacted over the past few years in this space.
Additionally, questions remain, such as:
- Are the cost savings of a two-in-one product worth the loss of flexibility that comes with dosing two agents independently?
- What is the place of bispecifics in the oncology world?
- What are the criteria for success in partnering in this space?
This webinar roundtable explores these interesting technologies, the scientific issues, the clinical opportunities for developing multivalent biologics platforms, whether certain technologies, such as antibodies, their fragments, or non-antibody scaffolds, are superior to others, the pros and cons of such bispecifics for improving the management of patients, and licensing and commercial strategies. Request a copy of the web discussion today!
MODERATOR AND PANELISTS:
Linda Pullan, PhD - Moderator
For over 10 years at Pullan Consulting, Linda Pullan has been helping in identification, evaluation, valuation, negotiation and strategy for partnering, in or out. She has an extensive deal sheet from company acquisitions to Phase III to preclinical candidates to technologies.
After a PhD in Biochemistry, Linda has over 20 years of industry experience, starting in drug discovery at Monsanto/Searle/Pfizer and ICI/Zeneca/AstraZeneca. She led teams that put Seroquel, a multi-billion dollar antipsychotic, and other molecules into development. Business development began with in-licensing technology and early drug candidates at AstraZeneca, and continued as head of oncology hematology licensing for Amgen. She then joined Kosan Biosciences as VP of Business Development, focusing on out-licensing. Linda also served as CEO of Viriome and on boards for Paloma and IRAD. Linda has spoken at many meetings, published papers and chapters.
Sanket Agrawal, MBA
Sanket provides commercial development and cross-functional leadership for Amgen’s oncology / hematology early pipeline (pre-clinical to late development) and therapy-area strategy initiatives for Amgen Oncology, integrating science with market insights to help develop differentiated and meaningful therapies for patients.
Executive Director, Global Oncology, Amgen
Earlier, he was Global Commercial Lead for Amgen’s mature oncology brands, built R&D outsourcing footprint in Asia/EU, managed M&A integrations, and delivered global transformation initiatives. He served Relsys International (acquired by Oracle) as Chief Strategy Officer, and Accenture and Deloitte where he was practice manager. He has also co-founded high-tech companies, raising capital and launching new products. He holds an MBA from the Anderson School at UCLA, MPH from University of Liverpool, and M.Eng from the University of Toronto. Learn More
Jeff Bockman, PhD
SVP, Head of Oncology Practice, Defined Health
Jeff leads the Oncology and Virology Practices at Defined Health. Jeff has extensive commercial and strategic perspective on the pharmaceutical and biotech industries. He has directed hundreds of in-depth licensing opportunity and valuation assessments during his tenure at DH. He often speaks at conferences on scientific and commercial issues in cancer, biologics and personalized medicine. Before joining Defined Health, Jeff was a Sr Research Scientist and Research Project Leader in the commercial development of oligonucleotide therapeutics for viral diseases and cancer at Innovir Laboratories; and an Assistant Research Professor at The George Washington University School of Medicine. He has worked closely with two Nobel Prize recipients: Dr. Sidney Altman on ribozymes, and Dr. Stanley Prusiner on prions, and holds four patents in the use of ribozymes.
He received a BA from UCSD, a PhD in Medical Microbiology from UCB, and an MA in English/Creative Writing from NYU. Jeff is a member of the Licensing Executives Society (LES), the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), and the American Society of Gene and Cell Therapy (ASGCT). Learn More
Ezio Bonvini, MD
SVP, Research and CSO, MacroGenics
Ezio Bonvini is the Senior Vice President of Research and Chief Scientific Officer at MacroGenics, Inc. A physician by training, he is an expert in immunobiology and drug development. Dr. Bonvini joined MacroGenics in 2003 after a career at the National Cancer Institute, NIH, and the Center for Biologics Evaluation and Research, FDA, where he last served as the Chief of the Laboratory of Immunobiology and the Acting Deputy Director of the Division of Monoclonal Antibodies. Dr. Bonvini has authored numerous publications in the field of signal transduction, immunology and immune-oncology and is an inventor on several patents. Learn More
Chris Hurff, MBA
Senior Director, Business Development, Takeda
Chris brings over twenty years of experience working in commercial and business development roles in oncology. Chris has negotiated a broad range of oncology business development transactions while at Takeda including discovery research collaborations in immune oncology, antibody drug conjugate platforms and CD3 bispecifics.
He also led a U.S. co-promotion agreement with a leading pharmaceutical company in multiple myeloma. Prior to joining Takeda’s Center for External Innovation, Chris led the VELCADE Brand Team in the U.S. and successfully launched several of the brand’s LCM indications. Chris holds an MBA from the Wharton School of Business and a bachelor’s degree in Biology from Dartmouth College. Learn More
Taylor H. Schreiber, PhD
CSO, Shattuck Labs
Dr. Schreiber is a physician/scientist with over a decade of experience developing immuno-oncology therapeutics. Taylor is the inventor of the Agonist Redirected Checkpoint (ARC™) platform and co-founder of Shattuck Labs.
Prior to Shattuck, he co-founded Pelican Therapeutics, which sprung from his work on the immunobiology of TL1A and TNFRSF25 at the University of Miami Miller School of Medicine. Dr. Schreiber also served as Chief Scientific Officer of Heat Biologics, Inc., and has published over 30 articles in prestigious peer-reviewed journals. Learn More
Ali Tehrani, PhD
President & CEO, Zymeworks
Dr. Tehrani is one of Zymeworks co-founders and currently serves as the President and Chief Executive Officer. Dr. Tehrani has served as a member of the board of directors since their inception in September 2003. He has been an integral part of many corporate achievements including raising seed and angel financing, as well as, overseeing technical operations and patent filings.
Dr. Tehrani holds both Bachelors and Masters of Science degrees in Biochemistry from the University of Massachusetts, and has a Doctoral degree in Microbiology and Immunology from the University of British Columbia. While completing his PhD he co-founded the Student Biotechnology Network, for which he received the UBC Faculty of Science Achievement Award for Outstanding Leadership in 2002. Dr. Tehrani has served as a Board Director for the Student Biotechnology Network, LifeSciences British Columbia, on the MITACS Industrial Advisory Board, and BIOTECanada’s Industrial and Environmental Committee. Currently, he is a member of the Board of Directors of Creatus Biosciences Inc., CQDM and the British Columbia Premier’s Technology Council. Learn More